TY - JOUR
T1 - HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event
AU - Horakova, Dana
AU - Zivadinov, Robert
AU - Weinstock-Guttman, Bianca
AU - Havrdova, Eva
AU - Tamaño-Blanco, Miriam
AU - Tyblova, Michaela
AU - Hussein, Sara
AU - Bergsland, Niels
AU - Willis, Laura
AU - Krasensky, Jan
AU - Vaneckova, Manuela
AU - Seidl, Zdenek
AU - Lelkova, Petra
AU - Ramanathan, Murali
PY - 2011/7
Y1 - 2011/7
N2 - Objectives: The presence of MRI lesions at the first demyelinating event increases the risk of developing clinically definite multiple sclerosis (MS). The HLA DRB1*1501 genotype is linked to MS susceptibility but its relationship to quantitative MRI parameters at the first demyelinating event has not been assessed.The objectives were to assess the associations between HLA DRB1*1501 status and magnetic resonance imaging (MRI) measures in clinically isolated syndromes (CIS) at the first demyelinating event. Methods: We genotyped 205 CIS patients (age: 29.0 ± 7.7. years) enrolled in the Observational Study of Early Interferon beta 1-a Treatment in High Risk Subjects after CIS (SET study), a multi-center, clinical study of CIS for rs3135005, a single nucleotide polymorphism associated with HLA DRB1*1501 status. The inclusion criteria required 2 or more brain MRI lesions and the presence of two or more oligoclonal bands in cerebrospinal fluid. Clinical and MRI assessments were obtained within 4. months of the initial demyelinating event. Results: The frequency of HLA DRB1*1501 positivity was 102/205 (49.7%). HLA DRB1*1501 positivity was associated with higher contrast-enhancing (CE) lesion number (p=0.002), higher CE-lesion volume (LV) (p
AB - Objectives: The presence of MRI lesions at the first demyelinating event increases the risk of developing clinically definite multiple sclerosis (MS). The HLA DRB1*1501 genotype is linked to MS susceptibility but its relationship to quantitative MRI parameters at the first demyelinating event has not been assessed.The objectives were to assess the associations between HLA DRB1*1501 status and magnetic resonance imaging (MRI) measures in clinically isolated syndromes (CIS) at the first demyelinating event. Methods: We genotyped 205 CIS patients (age: 29.0 ± 7.7. years) enrolled in the Observational Study of Early Interferon beta 1-a Treatment in High Risk Subjects after CIS (SET study), a multi-center, clinical study of CIS for rs3135005, a single nucleotide polymorphism associated with HLA DRB1*1501 status. The inclusion criteria required 2 or more brain MRI lesions and the presence of two or more oligoclonal bands in cerebrospinal fluid. Clinical and MRI assessments were obtained within 4. months of the initial demyelinating event. Results: The frequency of HLA DRB1*1501 positivity was 102/205 (49.7%). HLA DRB1*1501 positivity was associated with higher contrast-enhancing (CE) lesion number (p=0.002), higher CE-lesion volume (LV) (p
KW - Clinically isolated syndromes
KW - Genetics
KW - HLA
KW - MRI
KW - Multiple sclerosis
KW - Progression
UR - http://www.scopus.com/inward/record.url?scp=79960158179&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79960158179&partnerID=8YFLogxK
U2 - 10.1016/j.jneuroim.2011.04.011
DO - 10.1016/j.jneuroim.2011.04.011
M3 - Article
C2 - 21621859
AN - SCOPUS:79960158179
VL - 236
SP - 76
EP - 80
JO - Journal of Neuroimmunology
JF - Journal of Neuroimmunology
SN - 0165-5728
IS - 1-2
ER -